サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1791762

経口固形剤受託製造の世界市場

Oral Solid Dosage Contract Manufacturing

出版日
ページ情報
英文 172 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.53円
経口固形剤受託製造の世界市場
出版日: 2025年08月15日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 172 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

経口固形剤受託製造の世界市場は2030年までに609億米ドルに達する見込み

2024年に417億米ドルと推定される経口固形剤受託製造の世界市場は、2024年から2030年にかけてCAGR 6.5%で成長し、2030年には609億米ドルに達すると予測されます。本レポートで分析したセグメントの一つである錠剤は、CAGR7.3%を記録し、分析期間終了時には300億米ドルに達すると予想されます。CAGRは7.1%です。

米国市場は推定110億米ドル、中国はCAGR6.2％で成長予測

米国の経口固形剤受託製造市場は2024年に110億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに97億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは6.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ5.9%と5.6%と予測されています。欧州では、ドイツがCAGR 5.1%で成長すると予測されています。

世界の経口固形剤受託製造市場- 主要動向と促進要因まとめ

経口固形製剤（OSD）の受託製造が急拡大している理由とは？

経口固形製剤（OSD）受託製造市場は、製薬会社がコスト効率に優れた効率的な製造ソリューションを求める中で、力強い成長を遂げています。処方薬市場と一般用医薬品（OTC）市場の両方で錠剤、カプセル剤、ソフトジェルの需要が高まる中、製薬企業にとって開発・製造受託機関（CDMO）への製造委託は戦略的な動きとなっています。

加えて、規制要件の増加、価格圧力、製剤開発の複雑化により、製薬会社は専門のCDMOの専門知識を活用するようになっています。心血管障害、糖尿病、神経疾患などの慢性疾患の有病率の増加は、OSD医薬品の需要をさらに煽り、製造受託パートナーシップを推進しています。

技術の進歩はOSD受託製造をどのように強化しているか？

製造技術の革新は、OSD受託製造の展望を再構築しています。連続製造、3Dプリンティング、高度なコーティング技術は、生産効率、薬剤のバイオアベイラビリティ、患者のコンプライアンスを向上させています。高速圧縮・造粒技術は、一貫性と品質を向上させた大規模生産を可能にしています。

もう一つの重要な進歩は、製剤の最適化と予測的品質管理におけるAIと機械学習の利用です。CDMOは、リアルタイムのモニタリングを強化し、製造エラーを削減し、適正製造規範（GMP）の遵守を確保するために、スマート製造技術を統合しています。さらに、合剤（FDC）の増加により、より洗練されたOSD製造能力の必要性が高まっています。

特殊・高力価OSD医薬品の需要が市場動向を牽引？

特殊医薬品と高活性原薬（HPAPI）への注目の高まりが、受託製造の動向を変えています。CDMOは、腫瘍学、免疫抑制剤、中枢神経系（CNS）治療に使用される強力な化合物を取り扱うため、特殊な封じ込め施設や高度な設備に投資しています。

さらに、放出制御型および徐放性OSD製剤の需要が伸びており、CDMOは複雑な製剤技術に関する専門知識を拡大する必要があります。また、個別化医療の動向もOSD製造に影響を与えており、製薬会社は特定の患者のニーズに応える標的薬物送達ソリューションを模索しています。

経口固形剤受託製造市場の成長の原動力は？

OSD受託製造市場の成長は、費用対効果の高い医薬品製造に対する需要の高まり、規制の複雑化、専門的な製剤技術に対するニーズの高まりなど、いくつかの要因によってもたらされます。連続製造とAI主導の品質管理へのシフトは、効率性と拡張性をさらに高めています。

さらに、新興市場の拡大と慢性疾患の蔓延が、手頃な価格で高品質なOSD医薬品の需要を促進しています。医薬品製造をCDMOに委託する傾向の高まりは今後も続くと予想され、市場の着実な成長が期待されます。

セグメント

製品（錠剤、カプセル剤、粉末剤、顆粒剤、その他の製品）;機構（放出制御機構、即時放出機構、遅延放出機構）;エンドユーザー（大企業エンドユーザー、中堅・中小企業エンドユーザー、その他のエンドユーザー）

調査対象企業の例

  • AbbVie Contract Manufacturing
  • Aenova Group
  • Alcami Corporation
  • Almac Group
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent, Inc.
  • CMIC Holdings Co., Ltd.
  • Corden Pharma International
  • Delpharm
  • Hetero Labs Limited
  • Ind-Swift Laboratories Ltd.
  • Jubilant Pharmova Limited
  • Lonza Group AG
  • NextPharma
  • Patheon Pharma Services
  • Piramal Pharma Solutions
  • Recipharm AB
  • Rubicon Research Pvt. Ltd.
  • Siegfried Holding AG

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革します。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP32442

Global Oral Solid Dosage Contract Manufacturing Market to Reach US$60.9 Billion by 2030

The global market for Oral Solid Dosage Contract Manufacturing estimated at US$41.7 Billion in the year 2024, is expected to reach US$60.9 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2024-2030. Tablets, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$30.0 Billion by the end of the analysis period. Growth in the Capsules segment is estimated at 7.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$11.0 Billion While China is Forecast to Grow at 6.2% CAGR

The Oral Solid Dosage Contract Manufacturing market in the U.S. is estimated at US$11.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$9.7 Billion by the year 2030 trailing a CAGR of 6.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.9% and 5.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR.

Global Oral Solid Dosage Contract Manufacturing Market - Key Trends & Drivers Summarized

Why Is Contract Manufacturing for Oral Solid Dosage (OSD) Expanding Rapidly?

The oral solid dosage (OSD) contract manufacturing market is experiencing robust growth as pharmaceutical companies seek cost-effective and efficient production solutions. With the rising demand for tablets, capsules, and soft gels in both prescription and over-the-counter (OTC) markets, outsourcing manufacturing to contract development and manufacturing organizations (CDMOs) has become a strategic move for pharma companies.

Additionally, increasing regulatory requirements, pricing pressures, and the complexity of formulation development are prompting drug manufacturers to leverage the expertise of specialized CDMOs. The growing prevalence of chronic diseases such as cardiovascular disorders, diabetes, and neurological conditions is further fueling demand for OSD pharmaceuticals, driving contract manufacturing partnerships.

How Are Technological Advancements Enhancing OSD Contract Manufacturing?

Innovation in manufacturing technology is reshaping the OSD contract manufacturing landscape. Continuous manufacturing, 3D printing, and advanced coating techniques are improving production efficiency, drug bioavailability, and patient compliance. High-speed compression and granulation techniques are enabling large-scale production with improved consistency and quality.

Another key advancement is the use of AI and machine learning in formulation optimization and predictive quality control. CDMOs are integrating smart manufacturing technologies to enhance real-time monitoring, reduce production errors, and ensure compliance with Good Manufacturing Practices (GMP). Additionally, the rise of fixed-dose combination (FDC) drugs is driving the need for more sophisticated OSD manufacturing capabilities.

Is the Demand for Specialty and High-Potency OSD Drugs Driving Market Trends?

The increasing focus on specialty pharmaceuticals and high-potency active pharmaceutical ingredients (HPAPIs) is reshaping contract manufacturing trends. CDMOs are investing in specialized containment facilities and advanced equipment to handle potent compounds used in oncology, immunosuppressants, and central nervous system (CNS) treatments.

Additionally, the demand for controlled-release and extended-release OSD formulations is growing, requiring CDMOs to expand their expertise in complex formulation techniques. The growing trend of personalized medicine is also influencing OSD manufacturing, as pharma companies explore targeted drug delivery solutions that cater to specific patient needs.

What’s Driving the Growth of the Oral Solid Dosage Contract Manufacturing Market?

The growth in the OSD contract manufacturing market is driven by several factors, including the rising demand for cost-effective drug production, increasing regulatory complexity, and the growing need for specialized formulation expertise. The shift toward continuous manufacturing and AI-driven quality control is further enhancing efficiency and scalability.

Additionally, the expansion of emerging markets and the increasing prevalence of chronic diseases are fueling demand for affordable and high-quality OSD pharmaceuticals. The rising trend of outsourcing drug production to CDMOs is expected to continue, ensuring steady market growth in the years ahead.

SCOPE OF STUDY:

The report analyzes the Oral Solid Dosage Contract Manufacturing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Tablets, Capsules, Powders, Granules, Other Products); Mechanism (Controlled Release Mechanism, Immediate Release Mechanism, Delayed Release Mechanism); End-Use (Large Size Companies End-Use, Medium & Small Size Companies End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 36 Featured) -

  • AbbVie Contract Manufacturing
  • Aenova Group
  • Alcami Corporation
  • Almac Group
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent, Inc.
  • CMIC Holdings Co., Ltd.
  • Corden Pharma International
  • Delpharm
  • Hetero Labs Limited
  • Ind-Swift Laboratories Ltd.
  • Jubilant Pharmova Limited
  • Lonza Group AG
  • NextPharma
  • Patheon Pharma Services
  • Piramal Pharma Solutions
  • Recipharm AB
  • Rubicon Research Pvt. Ltd.
  • Siegfried Holding AG

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Oral Solid Dosage Contract Manufacturing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Pharmaceutical Outsourcing Trends Propel Growth of Contract Manufacturing Services
    • Surge in Generic Drug Consumption Drives Demand for Scalable Oral Solid Dosage Production
    • Strategic Focus on Core R&D Activities Strengthens Business Case for Outsourcing Manufacturing
    • Increasing Cost Pressures Among Mid-Sized Pharma Firms Expands Outsourcing Opportunities
    • Growing Demand for Orphan Drugs Unlocks Specialized Oral Solid Dosage Projects
    • Aging Global Population Sustains Long-Term Demand for Oral Solid Therapies
    • Rising Adoption of Fixed-Dose Combination Products Drives Innovation in Contract Manufacturing
    • Advancements in Continuous Manufacturing Technology Enhance Competitive Differentiation
    • Escalating Demand for High-Potency APIs Generates Opportunities for Specialized CMOs
    • Preference for Modified-Release Formulations Drives Adoption of Advanced Manufacturing Capabilities
    • Expansion of Emerging Pharma Markets Expands Addressable Market for Global CMOs
    • Implementation of Quality-by-Design (QbD) Practices Strengthens Regulatory Trust in CMOs
    • Technological Integration in Scale-Up and Tech Transfer Accelerates Client Acquisition
    • Growing Emphasis on Risk Mitigation and Operational Flexibility Fuels CMO Partnerships
    • Rise in FDA Approvals for Outsourced Drug Manufacturing Throws Spotlight on CMO Reliability
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Oral Solid Dosage Contract Manufacturing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Tablets by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Tablets by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Capsules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Capsules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Powders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Powders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Granules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Granules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Medium & Small Size Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Medium & Small Size Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Large Size Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Large Size Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Controlled Release Mechanism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Controlled Release Mechanism by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Immediate Release Mechanism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Immediate Release Mechanism by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Delayed Release Mechanism by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Delayed Release Mechanism by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Oral Solid Dosage Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Product - Tablets, Capsules, Powders, Granules and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Product - Percentage Breakdown of Value Sales for Tablets, Capsules, Powders, Granules and Other Products for the Years 2025 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by End-Use - Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use for the Years 2025 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Mechanism - Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Mechanism - Percentage Breakdown of Value Sales for Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism for the Years 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Product - Tablets, Capsules, Powders, Granules and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Product - Percentage Breakdown of Value Sales for Tablets, Capsules, Powders, Granules and Other Products for the Years 2025 & 2030
    • TABLE 34: Canada Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by End-Use - Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use for the Years 2025 & 2030
    • TABLE 36: Canada Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Mechanism - Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Canada 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Mechanism - Percentage Breakdown of Value Sales for Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism for the Years 2025 & 2030
  • JAPAN
    • Oral Solid Dosage Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Product - Tablets, Capsules, Powders, Granules and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Product - Percentage Breakdown of Value Sales for Tablets, Capsules, Powders, Granules and Other Products for the Years 2025 & 2030
    • TABLE 40: Japan Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by End-Use - Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Japan 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use for the Years 2025 & 2030
    • TABLE 42: Japan Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Mechanism - Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Japan 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Mechanism - Percentage Breakdown of Value Sales for Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism for the Years 2025 & 2030
  • CHINA
    • Oral Solid Dosage Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Product - Tablets, Capsules, Powders, Granules and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Product - Percentage Breakdown of Value Sales for Tablets, Capsules, Powders, Granules and Other Products for the Years 2025 & 2030
    • TABLE 46: China Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by End-Use - Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: China 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use for the Years 2025 & 2030
    • TABLE 48: China Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Mechanism - Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: China 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Mechanism - Percentage Breakdown of Value Sales for Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism for the Years 2025 & 2030
  • EUROPE
    • Oral Solid Dosage Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Product - Tablets, Capsules, Powders, Granules and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Product - Percentage Breakdown of Value Sales for Tablets, Capsules, Powders, Granules and Other Products for the Years 2025 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by End-Use - Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use for the Years 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Mechanism - Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Mechanism - Percentage Breakdown of Value Sales for Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism for the Years 2025 & 2030
  • FRANCE
    • Oral Solid Dosage Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 58: France Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Product - Tablets, Capsules, Powders, Granules and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Product - Percentage Breakdown of Value Sales for Tablets, Capsules, Powders, Granules and Other Products for the Years 2025 & 2030
    • TABLE 60: France Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by End-Use - Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: France 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use for the Years 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Mechanism - Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Mechanism - Percentage Breakdown of Value Sales for Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism for the Years 2025 & 2030
  • GERMANY
    • Oral Solid Dosage Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 64: Germany Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Product - Tablets, Capsules, Powders, Granules and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Product - Percentage Breakdown of Value Sales for Tablets, Capsules, Powders, Granules and Other Products for the Years 2025 & 2030
    • TABLE 66: Germany Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by End-Use - Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Germany 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use for the Years 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Mechanism - Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Mechanism - Percentage Breakdown of Value Sales for Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism for the Years 2025 & 2030
  • ITALY
    • TABLE 70: Italy Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Product - Tablets, Capsules, Powders, Granules and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Product - Percentage Breakdown of Value Sales for Tablets, Capsules, Powders, Granules and Other Products for the Years 2025 & 2030
    • TABLE 72: Italy Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by End-Use - Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Italy 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use for the Years 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Mechanism - Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Mechanism - Percentage Breakdown of Value Sales for Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism for the Years 2025 & 2030
  • UNITED KINGDOM
    • Oral Solid Dosage Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 76: UK Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Product - Tablets, Capsules, Powders, Granules and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Product - Percentage Breakdown of Value Sales for Tablets, Capsules, Powders, Granules and Other Products for the Years 2025 & 2030
    • TABLE 78: UK Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by End-Use - Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: UK 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use for the Years 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Mechanism - Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Mechanism - Percentage Breakdown of Value Sales for Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Product - Tablets, Capsules, Powders, Granules and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Product - Percentage Breakdown of Value Sales for Tablets, Capsules, Powders, Granules and Other Products for the Years 2025 & 2030
    • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by End-Use - Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Rest of Europe 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use for the Years 2025 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Mechanism - Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Mechanism - Percentage Breakdown of Value Sales for Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Oral Solid Dosage Contract Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Product - Tablets, Capsules, Powders, Granules and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Product - Percentage Breakdown of Value Sales for Tablets, Capsules, Powders, Granules and Other Products for the Years 2025 & 2030
    • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by End-Use - Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Asia-Pacific 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use for the Years 2025 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Mechanism - Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Mechanism - Percentage Breakdown of Value Sales for Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Product - Tablets, Capsules, Powders, Granules and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of World 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Product - Percentage Breakdown of Value Sales for Tablets, Capsules, Powders, Granules and Other Products for the Years 2025 & 2030
    • TABLE 96: Rest of World Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by End-Use - Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of World 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by End-Use - Percentage Breakdown of Value Sales for Medium & Small Size Companies End-Use, Other End-Uses and Large Size Companies End-Use for the Years 2025 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Oral Solid Dosage Contract Manufacturing by Mechanism - Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World 6-Year Perspective for Oral Solid Dosage Contract Manufacturing by Mechanism - Percentage Breakdown of Value Sales for Controlled Release Mechanism, Immediate Release Mechanism and Delayed Release Mechanism for the Years 2025 & 2030

IV. COMPETITION